Temple & Webster share price edges up after buy-back update as Citi turns more positive

February 16, 2026
Temple & Webster share price edges up after buy-back update as Citi turns more positive

Sydney, Feb 16, 2026, 18:44 AEDT — After-hours

  • Temple & Webster (TPW) traded 0.5% higher at A$7.64, ticking up from its prior close of A$7.60. 1
  • On Monday, the company posted a revised on-market share buy-back notice. 2
  • Citi bumped TPW up to a “buy” rating, moving it from “neutral” in its most recent broker call changes. 3

Temple & Webster shares picked up late Monday, following a regular update from the online furniture retailer on its ongoing share buy-back. 2

Investors are scrutinizing the move, still unsure if the stock truly bottomed after last week’s steep post-earnings slide. Buy-backs, seen as a show of balance-sheet strength, can sometimes throw a bit of support behind the share price. 1

TPW edged up to A$7.64, a 0.5% lift from its prior A$7.60 finish, Investing.com data showed. 1

First-half revenue climbed 19.8% to A$375.9 million, the company reported on Feb. 12. EBITDA, a measure of cash-style profit that strips out interest, tax, depreciation and amortisation, came in at A$13.5 million.

Temple & Webster stuck with its FY26 EBITDA margin target of 3% to 5%. Revenue climbed 20% year-on-year between Jan. 1 and Feb. 9, the company said.

The company, in that update, reported holding A$160.6 million in cash and carrying zero debt as of Dec. 31. It also disclosed spending A$7.5 million on an on-market buy-back through the half.

During the results call, CEO Mark Coulter made it clear to analysts that the company isn’t budging on its margin outlook. “Nothing has changed … our 3%-5% range for this year remains unchanged,” he said. 4

Analysts homed in on the weak spots during the call. Bell Potter’s Chami Ratnapala pressed management on whether recent margin softness and promotions are now delaying the “long-term EBITDA margin outlook.” 4

Citi bumped Temple & Webster up to a buy from neutral on Monday, the broker’s shift showing up in FNArena’s latest recommendation changes list. 3

But the risk is clear enough: should discounts continue or customer acquisition become pricier, margins could slip out of the target range while the company pushes for growth—meaning more pressure on the stock, and possibly more earnings cuts.

Traders now turn to Tuesday’s session (Feb. 17), eyeing whether momentum carries over after Monday’s buy-back filing. Fresh broker revisions could surface as coverage adjusts to last week’s results. 2

Stock Market Today

  • Australia Vials and Accessories Market Report: Size, Forecast, and Key Insights
    April 1, 2026, 8:12 AM EDT. The Australia Vials and Accessories market study offers a detailed analysis of sterile containers and components used in injectable pharmaceuticals. Covering market size, demand drivers, supply chains, pricing, and competitive structure, it serves manufacturers, investors, and strategic entrants. The report outlines market scope, segmentation by type and application, and regulatory contexts, projecting trends to 2035. Key insights include production bottlenecks, pricing factors, and landscape of market players. The study aids in identifying entry points, risk management, and expansion priorities within the pharmaceutical packaging sector in Australia.